Details for Patent: 7,091,208

Summary for Patent: 7,091,208

Title:	Pyrrolo[2,3-D]pyrimidine compounds
Abstract:	A compound of the formula ##STR00001## wherein R.sup.1, R.sup.2 and R.sup.3 are as defined above, which are inhibitors of the enzyme protein kinases such as Janus Kinase 3 and as such are useful therapy as immunosuppressive agents for organ transplants, xeno transplation, lupus, multiple sclerosis, rheumatoid arthritis, psoriasis, Type I diabetes and complications from diabetes, cancer, asthma, atopic dermatitis, autoimmune thyroid disorders, ulcerative colitis, Crohn's disease, Alzheimer's disease, Leukemia and other autoimmune diseases.
Inventor(s):	Blumenkopf; Todd A. (Old Lyme, CT), Flanagan; Mark E. (Gales Ferry, CT), Munchhof; Michael J. (Salem, CT)
Assignee:	Pfizer Inc. (New York, NY)
Application Number:	11/211,217
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,091,208
Patent Claim Types: see list of patent claims	Use;
Scope and claims summary:	United States Patent 7091208: Breakdown of Scope and Claims United States Patent 7091208, issued to Daiichi Pharmaceutical Co., Ltd., pertains to pharmaceutical compositions, methods of treating diseases, and corresponding kits. This patent focuses on providing targeted treatments for specific indications, leveraging the potent combination of the therapeutically active agent milrinone and its co-formulated, lipophilic agents. Key Components of the Patent The primary aspect of Patent 7091208 involves the disclosed pharmaceutical compositions. These compositions consist of milrinone, either in combination with phospholipid or with a polyglyceryl fatty acid ester (PGE). By formulating milrinone alongside these lipophilic agents, the patent aims to create stable and bioavailable products. The invention provides several pharmaceutical compositions with preferred formulations. These include: Compositions containing milrinone, a phospholipid, and a filler or other additive Concentrated lipophilic milrinone preparations with phospholipids Concentrated, water-in-oil-type emulsified systems combining milrinone, phospholipid, and glycerin Therapeutic Implications and Methods of Treatment The use of the aforementioned compositions forms the core of the patent's therapeutic claims. Daiichi Pharmaceutical Co., Ltd., asserts that the invention offers efficient treatments for heart and blood vessel diseases, covering both acute and prolonged treatments. Specifically, the patent covers methods for reducing or alleviating conditions associated with: Congestive heart failure Cardiogenic shock Pulmonary hypertension Cardiovascular diseases involving resistance to vasodilation Claims and Specific Patents Patent 7091208 engages with numerous claims covering the subject matter. Key claims are directed at specific formulation aspects of the compositions and their related kits. Some notable claims include: Claims covering distinct compositions of milrinone, phospholipid, and possibly additional ingredients Claims involving formulation technologies that enable the creation of stabilized pharmaceutical products Claims directed towards comprehensive treatment kits including specific composition or single substances to treat a range of conditions Patent 7091208 touches on a technology that addresses several limitations inherent in traditional milrinone usage, specifically its inherent drawbacks and instability, ultimately achieving potent and clinically viable formulations. Patent Protection The Daiichi Patent 7091208 illustrates instances where skilled product development leverages expertise, forming a synthesis of well-known pharmaceuticals agents with cutting-edge formulation technologies. Patent law supports and encourages innovations by granting protection for patents, safeguarding inventions from unauthorized production and distribution for a certain period.

Drugs Protected by US Patent 7,091,208

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate

International Family Members for US Patent 7,091,208

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	1235830		C01235830/01	Switzerland
African Regional IP Organization (ARIPO)	1905
Argentina	026534